Cover ImageSALE
Market Research Report

Global Non-insulin Diabetes Therapeutics Market 2018-2022

Published by TechNavio (Infiniti Research Ltd.) Product code 633215
Published Content info 101 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Non-insulin Diabetes Therapeutics Market 2018-2022
Published: April 13, 2018 Content info: 101 Pages
Description

About Non-insulin Diabetes Therapeutics

Non-insulin diabetes therapeutics are mostly administered orally and prescribed when diet and exercise are insufficient to control elevated blood glucose levels.

Technavio's analysts forecast the global non-insulin diabetes therapeutics market to grow at a CAGR of 11.37% during the period 2018-2022.

Covered in this report

The report covers the present scenario and the growth prospects of the global non-insulin diabetes therapeutics market for 2018-2022. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Non-insulin Diabetes Therapeutics Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AstraZeneca
  • Eli Lilly
  • Merck
  • Novo Nordisk
  • Sanofi

Market driver

  • Increasing number of people with type 2 diabetes
  • For a full, detailed list, view our report

Market challenge

  • High barriers to entry
  • For a full, detailed list, view our report

Market trend

  • Innovations in therapies
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents
Product Code: IRTNTR22520

Table of Contents

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022

PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of suppliers
  • Bargaining power of buyers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: MARKET SEGMENTATION BY TYPE

  • Overview
  • Comparison by type
  • DPP4 inhibitor - Market size and forecast 2017-2022
  • GLP-1 agonist - Market size and forecast 2017-2022
  • SGLT2 inhibitor - Market size and forecast 2017-2022
  • Others - Market size and forecast 2017-2022
  • Market opportunity by type

PART 08: CUSTOMER LANDSCAPE

PART 09: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Key leading countries
  • Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

  • Innovations in therapies
  • Strategic alliances between vendors
  • Increasing demand for combination drugs

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca
  • Eli Lilly
  • Merck
  • Novo Nordisk
  • Sanofi

PART 15: APPENDIX

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Parent market
  • Exhibit 02: Global diabetes therapeutics market: Segments
  • Exhibit 03: Market characteristics
  • Exhibit 04: Global non-insulin diabetes therapeutics market: Segments
  • Exhibit 05: Market definition: Inclusions and exclusions checklist
  • Exhibit 06: Market size 2017
  • Exhibit 07: Validation techniques employed for market sizing 2017
  • Exhibit 08: Global non-insulin diabetes therapeutics market 2017-2022 ($ millions)
  • Exhibit 09: Global non-insulin diabetes therapeutics market: Year-over-year growth 2018-2022 (%)
  • Exhibit 10: Five forces analysis 2017
  • Exhibit 11: Five forces analysis 2022
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Bargaining power of buyers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition: Five forces 2017
  • Exhibit 18: Segmentation by type: Market share 2017-2022 (%)
  • Exhibit 19: Comparison by type
  • Exhibit 20: DPP4 inhibitor 2017-2022 ($ millions)
  • Exhibit 21: DPP4 inhibitor: Year-over-year growth 2018-2022 (%)
  • Exhibit 22: GLP-1 agonist 2017-2022 ($ millions)
  • Exhibit 23: GLP-1 agonist: Year-over-year growth 2018-2022 (%)
  • Exhibit 24: SGLT2 inhibitor 2017-2022 ($ millions)
  • Exhibit 25: SGLT2 inhibitor: Year-over-year growth 2018-2022 (%)
  • Exhibit 26: Others 2017-2022 ($ millions)
  • Exhibit 27: Others: Year-over-year growth 2018-2022 (%)
  • Exhibit 28: Market opportunity by type
  • Exhibit 29: Customer landscape
  • Exhibit 30: Segmentation by geography: Market share 2017-2022 (%)
  • Exhibit 31: Regional comparison
  • Exhibit 32: Americas 2017-2022 ($ millions)
  • Exhibit 33: Americas: Year-over-year growth 2018-2022 (%)
  • Exhibit 34: EMEA 2017-2022 ($ millions)
  • Exhibit 35: EMEA: Year-over-year growth 2018-2022 (%)
  • Exhibit 36: APAC 2017-2022 ($ millions)
  • Exhibit 37: APAC: Year-over-year growth 2018-2022 (%)
  • Exhibit 38: Key leading countries
  • Exhibit 39: Market opportunity
  • Exhibit 40: Proportion of people aged 20-79 with diabetes 2015
  • Exhibit 41: Vendor landscape
  • Exhibit 42: Landscape disruption
  • Exhibit 43: Vendors covered
  • Exhibit 44: Vendor classification
  • Exhibit 45: Market positioning of vendors
  • Exhibit 46: AstraZeneca: Overview
  • Exhibit 47: AstraZeneca: Business segments
  • Exhibit 48: AstraZeneca: Organizational developments
  • Exhibit 49: AstraZeneca: Geographic focus
  • Exhibit 50: AstraZeneca: Key offerings
  • Exhibit 51: Eli Lilly: Overview
  • Exhibit 52: Eli Lilly: Business segments
  • Exhibit 53: Eli Lilly: Organizational developments
  • Exhibit 54: Eli Lilly: Geographic focus
  • Exhibit 55: Eli Lilly: Key offerings
  • Exhibit 56: Merck: Overview
  • Exhibit 57: Merck: Business segments
  • Exhibit 58: Merck: Organizational developments
  • Exhibit 59: Merck: Geographic focus
  • Exhibit 60: Merck: Key offerings
  • Exhibit 61: Novo Nordisk: Overview
  • Exhibit 62: Novo Nordisk: Business segments
  • Exhibit 63: Novo Nordisk: Organizational developments
  • Exhibit 64: Novo Nordisk: Geographic focus
  • Exhibit 65: Novo Nordisk: Key offerings
  • Exhibit 66: Sanofi: Overview
  • Exhibit 67: Sanofi: Business segments
  • Exhibit 68: Sanofi: Organizational developments
  • Exhibit 69: Sanofi: Geographic focus
  • Exhibit 70: Sanofi: Key offerings
Back to Top